Kisspeptin vs PT-141 is not a contest between two versions of the same libido drug. Kisspeptin starts the body's reproductive-hormone chain; PT-141 acts on a different set of signals in the brain. PT-141 has larger, 24-week treatment trials and a branded medicine for one narrow group. Kisspeptin has smaller, short studies that mainly measured hormones or brain activity. The practical answer is that a provider starts with the problem—low desire, arousal trouble, or abnormal hormone signaling—not with which peptide sounds stronger.
The two compounds have never been tested against each other in a published human trial. Calling either one the winner would go beyond the evidence.
Kisspeptin vs PT-141 at a glance
| Question | Kisspeptin | PT-141 (bremelanotide) |
|---|---|---|
| Main pathway | Starts reproductive-hormone signaling | Activates melanocortin receptors in the brain |
| Best human evidence | Small, single-infusion hormone and brain-imaging studies | Two 24-week phase 3 treatment trials |
| Who was studied | Healthy adults and small groups of men and premenopausal women with low desire | Mainly premenopausal women with acquired, generalized low desire; smaller early studies in men |
| U.S. approved product | None | Vyleesi, for a narrow group of premenopausal women |
| Main evidence gap | Long-term symptom and safety data | Evidence outside the labeled group |
That table is the short answer. The mechanism explains why these aren't substitutes, and the size of the studies explains why the confidence behind them is different.
The mechanism difference in plain English
Kisspeptin works upstream. It tells the hypothalamus, a small brain region that coordinates hormones, to release gonadotropin-releasing hormone (GnRH), the message that prompts the pituitary gland to act. The pituitary then releases LH and FSH, two signals that tell the ovaries or testes to work. Kisspeptin is not a replacement sex hormone; it asks an existing hormone system to respond.
PT-141 takes another route. It activates melanocortin receptors, docking points on nerve cells involved in central sexual signaling. The current Vyleesi label says binding at MC1R and MC4R matters most, while the exact way bremelanotide changes low desire remains unknown. It is not a blood-flow drug, and it is not intended to raise LH or testosterone.
What the human studies actually show
Kisspeptin's sexual-health file is interesting but early. In a 2017 study, 29 healthy young men received kisspeptin or placebo during different visits. Brain scans showed changes in areas responding to sexual and couple-bonding images (Comninos et al., Journal of Clinical Investigation, 2017). That was one monitored infusion, not a treatment course.
The later studies enrolled people with hypoactive sexual desire disorder (HSDD), meaning persistent low desire that causes distress. In 2022, 32 premenopausal women completed two research visits with a 75-minute kisspeptin-54 infusion or placebo; the study measured changes in sexual and attraction brain processing, not life outside the scanner (Thurston et al., JAMA Network Open, 2022). In 2023, 32 men completed a similar trial. Brain activity changed, and physical arousal measured during sexual video was up to 56% higher than with placebo (Mills et al., JAMA Network Open, 2023).
PT-141 has a larger treatment record, though it still applies to a specific population. The two RECONNECT phase 3 trials randomized 1,267 premenopausal women with acquired, generalized HSDD to bremelanotide or placebo for 24 weeks. The combined differences favored bremelanotide by 0.35 points on a desire score and by 0.33 points on a measure of distress about low desire. The count of satisfying sexual events did not differ significantly (Kingsberg et al., Obstetrics & Gynecology, 2019).
Early studies in men measured erection responses, not a durable improvement in desire, and Vyleesi's indication does not include men. The fuller evidence boundaries are covered in kisspeptin benefits and PT-141 benefits.
What changed in 2026
As of September 9, 2026, the day this article was written, the newest human kisspeptin administration study was published August 3 and tested repeated kisspeptin-10 infusions under the skin in 15 healthy men. Continuous exposure for five days lost much of the LH and FSH response, while an eight-hours-on, sixteen-hours-off research pattern maintained higher hormone signals through 12 days. It did not test libido, compare kisspeptin with PT-141, or establish a take-home schedule (Yeung et al., European Journal of Endocrinology, 2026).
On August 24, FDA also sent a warning letter about a specific online seller's PT-141 product. The letter concerned how that seller presented and sold injectable products without an approved application. It was not a new clinical safety finding about bremelanotide, and it did not change Vyleesi's status. The practical difference is accountability: a patient-specific prescription filled by a licensed U.S. compounding pharmacy has a prescriber, a pharmacy of record, and a traceable dispensing record.
Side effects and approval are not footnotes
PT-141 has the clearer frequency data. About 2 in 5 people in the Vyleesi trials reported nausea (40%). Flushing, injection-site reactions, headache, and vomiting were also common. The label describes a temporary blood-pressure rise after each dose and lists uncontrolled hypertension or known cardiovascular disease as contraindications, meaning reasons the branded medicine should not be used.
Kisspeptin looks quieter only because the record is much smaller. The 2022 and 2023 single-infusion studies reported no adverse effects, but they watched 32 women and 32 men for hours, not a broad population for months. Kisspeptin-10 also leaves the blood quickly: half-life, the time needed to clear half of it, is about four minutes. How kisspeptin works and clears explains why the hormone response can outlast the peptide.
Compounded PT-141 is different from FDA-approved Vyleesi: the formulation offered here is not FDA-approved. No kisspeptin product is FDA-approved, and the compounded formulation offered here is not FDA-approved. Compounded medications are not reviewed by FDA for safety, effectiveness, or quality. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor.
Which question is the provider trying to answer?
For a premenopausal woman with acquired, generalized low desire that causes distress, PT-141 has evidence closer to that exact problem. When the question involves whether the reproductive hormone system can respond, kisspeptin's upstream mechanism may be relevant, but its libido evidence is still early. For men, both records are smaller and neither supports borrowing Vyleesi's indication.
Low desire can also trace back to a medication, mood, sleep, thyroid function, menopause, relationship strain, pain, or a blood-flow problem. That is why the useful comparison is not simply which injection to choose. It is which cause is being evaluated, which result would be meaningful, and which risks the person's history changes.
At Promise, a licensed provider reviews every request and not everyone qualifies. The provider sets the formulation and plan if a prescription is appropriate, or declines when neither compound fits.